SCHEMBL7621072

SCHEMBL7621072

COc1nc(C)c(C)cc1NC(=O)N1CCC(=C(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PDE10A Q9Y233 2/20 0.41
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
SETD7 Q8WTS6 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
FAAH O00519 2/20 0.40
ABCC1 P33527 1/20 0.40
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
THRB P10828 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6652808 0.83 RBP4 (0.57) MAPK1KDM4ELMNATP53MAPT
SCHEMBL7618187 0.82 OPRD1 (0.47) PKMMAPK1KDM4ETDP1SMN1; SMN2
SCHEMBL7617468 0.81 CACNA2D1 (0.48) TDP1SMN1; SMN2LMNAMAPTHTT
SCHEMBL6966645 0.79 MAPT (0.60) KDM4ETDP1LMNAMAPTHTT
SCHEMBL9058218 0.78 PANK3 (0.62) MAPK1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL8700515 0.77 KDM4E (0.48) PKMMAPK1KDM4ELMNAMAPT
SCHEMBL15920000 0.77 TAS1R3 (0.66) PKMMAPK1KDM4ETDP1RAB9A
SCHEMBL6954279 0.77 KMT2A (0.49) MAPK1SMN1; SMN2LMNATP53MAPT
SCHEMBL8705827 0.77 LMNA (0.61) MAPK1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL27484486 0.77 KMT2A (0.62) PKMMAPK1SMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same CHACONNE NSI CO., LTD. (KR) 2002-02-14 US claimed
WO-2001095856-A2 UREA DERIVATIVE USEFUL AS AN ANTI-CANCER AGENT AND PROCESS FOR PREPARING SAME CHACONNE NSI CO., LTD. (KR) 2001-12-20 WO claimed
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same CHACONNE NSI CO., LTD. (KR) 2002-02-14 US disclosed
WO-2001095856-A2 UREA DERIVATIVE USEFUL AS AN ANTI-CANCER AGENT AND PROCESS FOR PREPARING SAME CHACONNE NSI CO., LTD. (KR) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same UTS2R, SLC14A1, URB2 PKM 3518/4885MAPK1 1142/4885FNTA 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.